Chinese humanoid robots gallop towards consumer market

CGTN published an article on robot performances during China Media Group’s 2026 Spring Festival Gala. When the Year of the Horse arrived in 2026, all eyes were on China’s Spring Festival Gala. What unfolded was more than a cultural spectacle – it was a hard-tech showcase. Humanoid robots have become a recurring Gala centerpiece, signaling China’s push for next-generation AI-powered robotics. While some Western counterparts remain stuck as expensive prototypes, China’s strategy is moving from lab to production line. The cycle from spectacle to store is complete – and the world is watching.

Chinese humanoid robots have officially moved from lab prototypes to the center of the global stage.

At this year’s CMG Spring Festival Gala, the world’s most-watched television broadcast, four Chinese robotics powerhouses, namely Unitree, MagicLab, Galbot and Noetix, debuted their most advanced units to date. For the robotics industry, this was far more than a cultural performance; it was a high-stakes global product launch.

Global media hails China’s robot showcase

The Associated Press noted that humanoid robots have become a recurring Spring Festival Gala centerpiece – a clear signal of “China’s push to develop more advanced robots powered by improved AI capabilities.”

Major broadcasters like CBS praised the “seamless movements” of the units, while Spain’s El Español hailed the robots’ evolution from 2025 to 2026 as a “veritable revolution.” Last year’s robots were stiff and mechanical, but this year’s Unitree G1 units moved with fluidity and freedom, it said. The report also noted that the robots are commercial products – already available in Spain.

A window to China’s industry policies

The story of the “Gala Robot” can be traced as early as 2016 when the Shenzhen-based UBTECH debuted 540 small humanoid robots. By this year’s gala, the stage became unprecedentedly crowded with four distinct companies vying for a position.

Fueled by breakthroughs in artificial intelligence, the humanoid robotics sector has advanced at a pace beyond expectations. CMG data shows that China recorded over 140 humanoid robot manufacturers in 2025 with more than 330 humanoid robot models launched.

The explosion is a direct result of China’s humanoid industrial clusters, and this year’s performance reflects China’s industry policies, according to Reuters.

In 2025, “embodied AI” was written into China’s Government Work Report for the first time, signaling its elevation to a top-tier strategic priority. This momentum was further solidified in the Recommendations of the Communist Party of China Central Committee for Formulating the 15th Five-Year Plan for National Economic and Social Development, which identified embodied AI among “new drivers of economic growth.”

Following this central guidance, local governments across China have rapidly integrated humanoid robotics into their economic blueprints, rolling out specialized support policies and incentives to secure a leading position in this high-stakes global race.

Reshaping the global industrial landscape

In the sketch comedy, Noetix’s “Bumi” robot navigated the nuances of a family skit, using humor to bridge the gap between a machine and a companion. In the short film, the robot was shown performing chores in a real-world home.

“Ultimately, technology is meant to serve people, not just exist for the sake of the technology itself,” Unitree’s founder Wang Xingxing said in an interview with CMG.

This vision is already translating into massive market demand. Within the first two hours of the Gala’s broadcast, searches for robots on an e-commerce platform surged more than 300 percent compared to the previous period. Customer inquiries increased by 460 percent, and order volumes rose by 150 percent. The new orders covered over 100 cities nationwide, spanning from first-tier metropolises to smaller counties.

Noetix CMO Zhang Miao explained to the press that China has moved from the factory floor to the commercial channel. “The real measure of a company’s health is no longer how many robots it can build, but how many it can successfully integrate into real-world scenarios.”

A new era of robotics is now taking shape – and it is firmly rooted in China.

For more information, please click:

https://news.cgtn.com/news/2026-02-17/China-s-robots-ready-to-walk-off-the-stage-and-into-a-store-near-you-1KQnpNZa8Io/p.html

ChimpX AI Enters Final Presale Phase on AlphaMind, Strengthening Its BNB Chain–Powered Ecosystem

The blockchain industry has reached a crossroads where scalability is no longer the only challenge; the true hurdle is now usability. As the BNB Chain ecosystem demonstrates remarkable resilience in early 2026—maintaining a market cap of over $90 billion despite wider market volatility—the launch of ChimpX AI’s Mojo SuperApp marks a pivotal moment for the network. By integrating AI-driven automation with the chain’s high-performance infrastructure, ChimpX AI is positioning itself as the primary gateway for retail users to enter the “Zero-Fee” era of decentralized finance.

Building on a Titan: Why BNB Chain?

The choice to launch the Mojo SuperApp (live at app.chimpx.ai) on the BNB Chain was a calculated move by the ChimpX AI development team. In 2026, the BNB Chain has evolved beyond being “just a fast EVM.” Following the successful Fermi hard fork in January, which slashed block times to 0.45 seconds, the network is now aggressively pursuing a roadmap of 20,000 transactions per second (TPS).

However, high TPS is meaningless if the average user is still intimidated by the technical debt of Web3. This is where ChimpX AI creates value. While the BNB Chain provides the “highway,” ChimpX AI’s Mojo SuperApp provides the “autonomous vehicle.” By utilizing Account Abstraction, Mojo removes the traditional requirement for users to hold native BNB for gas—a friction point that has historically alienated millions of potential retail participants.

The ‘DefAI’ Advantage in a Recovering Market

Current market conditions in February 2026 suggest a significant structural reversal. Bitcoin has found a solid floor above $61,000, and institutional interest is rotating into utility-dense sectors like DefAI (DeFi + AI) and Real-World Assets (RWA). Within this environment, ChimpX AI stands out by offering a live, functional product during its pre-sale phase.

The “Mojo” experience allows for seamless token swaps, lending, and portfolio management without the hassle of manual fee adjustments. As BNB Chain expands its “Zero-Fee” extensions, projects like ChimpX AI are the frontline beneficiaries, capturing the influx of new users who demand a mobile-first, “Web2-easy” interface.

Final Pre-Sale Round: The Path to $4M FDV

The momentum behind ChimpX AI is undeniable. Having already sold out public IDO rounds on SPORES and Poolz Finance—even during the “sideways” market movements of early Q1—the project has now moved into its final pre-sale stage on AlphaMind.

This AlphaMind round offers $CHIMP at $0.25 per token, valuing the project at a $4 million Fully Diluted Valuation (FDV). For an ecosystem already hosting a live SuperApp and a community of thousands, this valuation is seen by many as a major market inefficiency. As the project prepares for its PancakeSwap listing in February, the pre-sale represents the final opportunity for investors to acquire $CHIMP at institutional-grade prices.

A Wealth Generation Perspective

Market analysts are closely watching the $CHIMP price outlook for 2026–2027. With BNB projected to retest its four-figure all-time highs and potentially reach $1,200+ by 2027, the tokens that provide the most utility within that ecosystem are expected to see the highest beta.

For $CHIMP, the roadmap is clear:

  • Q1 2026: Establish a strong secondary market following the PancakeSwap debut.
  • Late 2026: Scale Mojo user base to 100,000+ active wallets.
  • 2027: Integrate advanced AI agents for automated, cross-chain yield strategies.

How to Participate in the Movement

The AlphaMind pre-sale is currently the most direct way to gain exposure to the ChimpX AI ecosystem ahead of the February listing. With a maximum commitment of $15,000 per wallet and a 25% TGE unlock, the round is designed to foster a decentralized and healthy holder base.

Investors can secure their allocation at https://app.alphamind.co/ido/6989a7df51f2ab92207ec335?invite=rmzD-2dY

To join the discussion and stay updated on the exact PancakeSwap listing time, the community is active 24/7 on Telegram at https://t.me/chimpxofficial.

About ChimpX AI ChimpX AI is a decentralized technology firm focused on simplifying the blockchain experience through the power of Artificial Intelligence. Its flagship product, Mojo, is a gasless DeFi SuperApp that abstracts the complexities of the BNB Chain for a global audience.

Official Community & Apps:

RWA Summit Hong Kong 2026: The Definitive Bridge Between TradFi and On-Chain Realities

The RWA Summit Hong Kong has come to an end—an exciting event that has cemented the city’s status as the world’s leading center for real asset tokenization (RWA). These were two intense days when more than 700 carefully curated participants, 50+ distinguished speakers, and 80+ leading institutional investors gathered to map out the future of DePin, stablecoins, and the move toward bringing TradFi on-chain.

Rather than revisiting whether tokenization is viable, discussions focused on how it can be executed within credible legal, financial, and operational frameworks.

“RWA SUMMIT Hong Kong was not just another event for us, it was a place where real deals and business happened. We were proud to co-host the event and bring together potential partners, regulators and market leaders. It’s a great opportunity to present our bonds tokenization and DeFi projects to both TradFi and Digital Assets players. I believe that the key result of any event are the real deals that follow. RWA SUMMIT is definitely this kind of event. No noise, no hype, only real expertise of speakers, and a highly curated network”Peter Kadish, Managing Director LynxCap Investments, RWA SUMMIT Hong Kong co-host.

The RWA Summit clearly showed that tokenization has moved beyond theory into execution,” says Scott Thiel, co-founder & CEO of Tokinvest. “Across panels on venture capital, IP tokenization, and institutional adoption, the focus was on infrastructure, liquidity planning, and trusted market frameworks.

And this is how Gillian Wu, founder and CEO of Mulana Investment Management, comments on the insights of the event: “At the RWA Summit during Consensus Hong Kong, we explored how real-world assets are bringing wealth on-chain through greater efficiency, transparency, disintermediation, and fractionalized ownership. Tokenization, however, does not change the fundamental factors that influence value, and investors must carefully assess counterparty risk and liquidity. Although market fragmentation and structural differences between DeFi, exchanges, and traditional finance remain challenges, progress toward convergence is evident.

Day 1: Forging Regulatory Pathways and Institutional Momentum

The summit opened with remarks from Joseph Chan, Under Secretary for Financial Services and the Treasury of the Hong Kong Government, who highlighted Hong Kong’s regulatory direction and its ambition to provide clarity for tokenized financial products. The message was consistent throughout the day: regulatory structure is no longer an obstacle but a prerequisite for scale.

The day included four spotlight sessions.

The first one was on global frameworks. The participants got a profound exploration of regional RWA trends, featuring insights from Scott Thiel (Tokinvest), Julian Kwan (InvestaX), and Terence Ng (EX.IO), expertly moderated by Peter Kadish (LynxCap). The takeaway? Regulation has evolved from a barrier into a strategic advantage.

Thereafter, we covered the AI convergence. Alan Lau (Animoca Brands) and Geoff Kot (Standard Chartered) delved into how artificial intelligence is revolutionizing the connection between traditional banking and digital asset ecosystems.

Another essential point was related to banking giants on-chain. Bugra Celik (HSBC) and Giorgia Pellizzari (Hex Trust) highlighted the transition from experimental proof-of-concept to full-scale institutional adoption, emphasizing robust custody and security for digital currencies.

The day concluded with a forward-looking exchange between Nenter Chow of Bitmart and Sébastien Borget of The Sandbox. They explored how crypto-native ecosystems are incorporating RWAs. The conversation centered on sustainable value creation rather than short-term market cycles.

“At the RWA Summit in Hong Kong, we discussed how blockchain is expanding from virtual real estate to collectible assets and user-generated content revenues being tokenized on-chain. The direction is clear: blockchain technology will become broadly adopted across gaming, digital assets, and the creator economy. It will ultimately integrate so seamlessly into user experiences that people benefit from it without needing to think about the underlying infrastructure,” shares Sébastien Borget, co-founder of SandBox & SandChain.

The first day also featured an outstanding lineup of industry leaders and innovators, including Cathal Donnellan, President at NexStox; Marcos Chow, Group CIO at HKT; Rocky Mui, Partner at Clifford Chance; Tom Wan, Partner at Imprint Capital Partners; Neil Tan, Managing Partner at Tsunami Advisors and Chairman of the AI Association of Hong Kong; Phillip Pon, CEO at EMURGO; Andrei Grachev, Managing Partner at DWF Labs; Musheer Ahmed, Founder & CEO at FinStep Asia; Jelena Zhang, SVP at Amber Premium; Jayendra Jog, Co-Founder at Sei Labs; Nikita (Sachdev) Lord, Founder & CEO at Luna PR; Edwin Mata, Co-Founder & CEO at Brickken; Preetam Rao, Co-Founder & CEO at QuillAudits; and Leo Fan, Founder & CEO at Cysic.

Day 2: Envisioning Tomorrow’s Wealth, IP, and Payment Innovations

The second day shifted toward applied use cases, examining how tokenization is reshaping wealth management, intellectual property, and payment systems.

The second day of RWA Summit opened with a high-level fireside chat featuring Sean McHugh, Senior Director – Market Assurance at VARA (Virtual Assets Regulatory Authority). The discussion set the tone for the day, focusing on regulatory clarity, market integrity, and the evolving framework for virtual assets in the region.

In a fireside discussion, Yat Siu of Animoca Brands and Bowie Lau of MaGE Group analyzed the implications of IP tokenization for content platforms and creator economies for giants like YouTube, Spotify, and Netflix. The conversation focused on whether blockchain-based models can provide more direct monetization and ownership structures while maintaining compliance and investor protections.

A recurring theme in our discussion was that RWA is not about “putting a single asset on-chain”; it’s about modernizing financial infrastructure without breaking law, trust, or market structure, comments Jeffrey Broer, venture advisor at Kohpy Ventures. “Tokenization within a regulated environment does not automatically create liquidity, and lower minimums do not mean retail access. True liquidity requires credible market design and participation. For venture-backed startups, the real opportunity lies in compliance-native infrastructure, settlement and orchestration layers, custody, risk tooling, and transparency rails. In short, the value is in building the plumbing, not chasing product hype.

Wealth migration onto blockchain infrastructure was addressed by Ray Tam of Revo Digital Family Office and Florian M Spiegl of Evident Capital. They tackled the hurdles of onboarding professional investor (PI) wealth onto the blockchain while unveiling exciting avenues for retail investors.

The next spotlight session of the day was on the PayFi Revolution. Rita Liu (RD Technologies) and Evan Auyang (Animoca Brands) offered a grounded perspective on stablecoins and payment finance in the “Asian Reality.”

The 2-day event concluded with a comparative discussion featuring Pauline Fan of InvestHK, Rachel Lee of Cyberport, and Irina Heaver of RWA Labs. The panel assessed Hong Kong’s regulatory agility against competitors like the UAE and beyond.

The stage then welcomed an exceptional lineup of investors, founders, and industry leaders, including Noah Frankel, Investment Analyst at JSquare; Tobias Bauer, General Partner at TBV; Calvin Ng, General Partner at Plutus VC; Melody He, Co-Founder & Partner at Spartan Group; Craig Dyer, Head of Capital Markets at HECTO; Pauli Speaks, CBDO at Cryptic; DiZien Low, Director of Business Development at Polygon Labs; Jacky Kong, Head of Hong Kong at Ava Labs; Sonia Shaw, CEO at OneAsset; Andrey Fedorov, CMO & CBDO at STON.fi; Jackee Wong, Partner & CMO at Leadsourcing; Sudeep Mehta, COO at STBL; and Lawrence Tsui, Director of Business Development and Strategic Solutions for Hong Kong & Mongolia at Fortinet.

Special thanks to the partners of RWA Summit, in particular our Strategic Partner, BTSE Enterprise Solutions, and our Partner, STON.fi, for their invaluable support and contribution to the event’s success.

Industry Developments and Expansion

Apart from panel discussions, the summit also provided a platform for industry announcements. LynxCap introduced its DeFi platform designed to connect RWA yield strategies with structured liquidity environments. In parallel, Ivan V. Ivanov of UVECON.VC and Irina Heaver of RWA Labs announced the launch of Dubai RWA Week 2026, signaling increased collaboration between Asian and Middle Eastern tokenization hubs.

RWA Summit Hong Kong brought together strong voices from both TradFi and digital assets,” says Ivan V. Ivanov, founder of RWA Summit. “The discussions focused on execution, regulation, and real market structure and were grounded in actual cases, not theory.

What stood out to me most was the growing alignment between ecosystems like Hong Kong and Dubai. Different frameworks—and clear potential for collaboration. Our goal was to create a platform where real experts share real cases, challenges, and practical paths forward. Judging by the depth of discussion, we are clearly moving in the right direction.

To sum it up, the RWA Summit Hong Kong 2026 has unequivocally demonstrated that the dialogue has advanced from “Is this feasible?” to “How swiftly can we expand?” By bridging TradFi’s regulatory rigor with DeFi’s tech stack, we’re moving toward a financial system that is actually transparent and accessible, not just fast.

Axblade Marks Strategic Debut at Consensus Hong Kong 2026, Sets Clear Course for Compliant Finance  Infrastructure

Hong Kong — February 18, 2026Axblade, a high-performance hybrid finance protocol, made its first international appearance at Consensus Hong Kong 2026, the premier Web3 conference held February 11–12 at the Hong Kong Convention & Exhibition Centre. The debut marked the protocol’s formal entry into the global stage, distinguished by sustained engagement at its exhibition booth, senior-level dialogue, and the early disclosure of its next-phase roadmap.

Debut Draws Sustained Engagement, Spotlight on Compliance-by-Architecture

According to public remarks from Hong Kong’s Deputy Secretary for Financial Services and the Treasury, Christopher Hui, Consensus Hong Kong 2026 convened over 15,000 attendees from more than 100 countries and regions. Against this backdrop, Axblade’s exhibition booth maintained consistent traffic throughout the two-day event. All 500 Axblade units of custom merchandise were distributed amid vibrant, ongoing conversations at the booth.

Axblade Cofounder & COO Liam was on site for the duration of the conference, engaging directly with developers, institutional representatives, and compliance professionals from Asia, Europe, the Middle East, and beyond. The vast majority of conversations converged on a single structural question: how to bridge real-world assets onto chain with verifiable integrity while satisfying multi-jurisdictional regulatory requirements.

“The industry is no longer debating whether on-chain finance can be compliant—it’s asking what genuine compliance looks like at the architecture level,” COO Liam said during booth discussions. “The real dividing line is whether compliance is patched on as a constraint or embedded as a design feature. Axblade is built on the latter premise—not compliance that compromises performance, but compliance that performs. ”

What Axblade Is: A Finance Protocol Built on a Compliance-first Foundation

Faced with repeated inquiries about the protocol’s core identity, the Axblade team offered a consistent, distilled answer:

Axblade is an on-chain finance protocol engineered from the ground up for regulatory alignment.

“Compliance isn’t an add-on. It’s the foundation,” COO Liam said. “A structure without a foundation is a tent. We’re building permanent infrastructure.”

Unlike protocols that treat compliance as an access control layer or a post-hoc modification, Axblade embeds a programmable compliance framework at the base layer. This architecture enables verifiable data, programmable permissions, and auditable asset provenance—without unnecessary exposure of personal or institutional information. It is designed to support high-throughput, cross-border transactions while remaining adaptable to evolving regulatory regimes across jurisdictions.

Next Milestone: RWA Data Verification & Provenance Solution Due Q2 2026

Axblade also used its Consensus debut to provide early visibility into its next major development focus: data verification and provenance for tokenized real-world assets.

A persistent gap in today’s RWA landscape is the disconnect between asset representation on-chain and the verifiability of off-chain reality. Questions of physical existence, clear title, and continuous state validation remain largely unstandardized and unsolved.

Axblade confirmed that an institutional-grade framework for RWA data verification and provenance is in advanced development, with formal release targeted for Q2 2026. The solution is expected to combine zero-knowledge proofs, decentralized identity primitives, and on-chain state synchronization to establish cryptographically anchored assurances for real-world assets.

“Tokenizing an asset isn’t about putting a PDF on IPFS,” COO Liam noted. “True RWA integration means every unit of on-chain value retains a deterministic link to its off-chain source of truth.”

About Axblade

Axblade is a high-performance, hybrid finance protocol purpose-built to bridge real-world assets and on-chain liquidity. Through a compliance-native architecture and settlement-grade execution environment, Axblade enables capital to be issued, composed, and deployed across borders—programmably, transparently, and in alignment with regulatory requirements. Its long-term vision is to serve as foundational infrastructure for the next generation of on-chain finance.

Micah J. Chapman Releases Memoir The Book of Micah

Author Micah J. Chapman has published a new memoir titled “The Book of Micah: A Journey from Survival to Purpose,” now available on Amazon and in bookstores nationwide.

The memoir chronicles Chapman’s personal experiences growing up between two households in the Rocky Mountains. The narrative covers his childhood, adolescence, and the challenges he faced during those formative years, including family separation, economic hardship, and periods of personal struggle.

Chapman’s account details his experiences with abandonment, poverty, and the process of navigating difficult circumstances during his youth. The book examines how these experiences shaped his perspective and eventual path forward.

“The Book of Micah” is structured as a chronological narrative, taking readers through various stages of the author’s life. The memoir explores themes of resilience, personal development, and overcoming adversity. The narrative spans multiple decades, beginning with Chapman’s early childhood years and continuing through his adolescence and young adulthood.

Throughout the narrative, Chapman addresses topics including family dynamics, the impact of geographical displacement, and the process of personal growth following periods of instability. The book examines both the immediate and long-term effects of childhood experiences on adult development.

The memoir is written in first-person perspective and incorporates reflective commentary on the author’s experiences. Chapman provides context for the events described and offers observations on how past circumstances influenced his life decisions.

The book documents Chapman’s transition from challenging early life conditions to a more stable foundation. The author traces his personal development through various life stages and the factors that contributed to changes in his circumstances.

“The Book of Micah” provides readers with an account of one individual’s experience navigating difficult family situations and the process of building a different future. The memoir is intended for readers interested in personal narratives about overcoming hardship.

Micah J. Chapman is a first-time author whose memoir draws from his personal experiences growing up in the Rocky Mountain region. “The Book of Micah: A Journey from Survival to Purpose” represents his debut publication.

The book is currently available for purchase through Amazon and select bookstores across the United States. 

Media Contact

Organization: Micah J Chapman

Contact Person: Micah J Chapman

Website: http://micahjchapman.com/

Email: Send Email

Contact Number: +19038803640

Country:United States

Release id:41369

The post Micah J. Chapman Releases Memoir The Book of Micah appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section

file

Health Connect Alliance Names CoreAge Rx Best GLP-1 Provider for Weight Management in 2026, Awards 9.9-10 Rating and Editor’s Choice Designation

Miami, FL 33101, United States, 18th Feb 2026 –Health Connect Alliance, an independent health education platform that provides reviews and guidance on GLP-1 medications and treatment providers, has released its rankings of telehealth platforms offering GLP-1 medications and named CoreAge Rx as the #1 recommended provider for weight management in 2026. The independent review evaluated more than 48 GLP-1 providers and awarded CoreAge Rx a 9.9 out of 10 rating, along with its Editor’s Choice designation and an A+ rating.

According to Health Connect Alliance, the rankings were based on key evaluation criteria including medical supervision, medication quality, treatment personalization, pricing transparency, and ongoing medical support. CoreAge Rx ranked at the top of the platform’s “Best Place to Get GLP-1 Medications” category, receiving the highest score among all reviewed providers.

The rankings page published by Health Connect Alliance lists CoreAge Rx as its #1 recommended GLP-1 provider, highlighting its premium GLP-1 program, access to FDA-approved semaglutide and tirzepatide, personalized treatment plans, and care provided under the supervision of board-certified physicians. The review also identifies CoreAge Rx as its “Editor’s Choice,” recognizing it as the platform’s top overall recommendation for GLP-1 treatment programs.

In its overall recommendation, Health Connect Alliance states that CoreAge Rx stands out as its top choice for individuals seeking GLP-1 medications for weight management. The platform notes that CoreAge Rx offers personalized treatment plans designed by board-certified physicians and provides ongoing medical supervision throughout treatment.

Health Connect Alliance’s editorial analysis outlines several factors that contributed to CoreAge Rx receiving the highest rating. One of the primary factors is medical supervision, which the platform identifies as a critical requirement for safe and legitimate GLP-1 treatment. The review emphasizes that reputable providers must require consultation with licensed healthcare professionals, conduct comprehensive health evaluations, and provide ongoing medical monitoring. CoreAge Rx was recognized for offering treatment programs overseen by board-certified physicians, ensuring clinical oversight throughout the treatment process.

Medication quality and sourcing were also identified as essential components in the rankings. Health Connect Alliance states that high-quality GLP-1 providers offer FDA-approved medications such as semaglutide and tirzepatide or compounded medications prepared by licensed compounding pharmacies that follow regulatory standards. The platform highlights that CoreAge Rx offers FDA-approved semaglutide and tirzepatide as part of its GLP-1 program.

Health Connect Alliance also notes the importance of personalized treatment plans in achieving successful outcomes. According to the review, personalized treatment plans allow healthcare providers to assess patient medical history, monitor progress, and adjust treatment protocols as needed. CoreAge Rx was recognized for providing individualized treatment plans developed and supervised by board-certified physicians.

The platform further emphasizes the importance of ongoing medical support throughout treatment. Health Connect Alliance explains that ongoing medical supervision allows healthcare providers to monitor progress, address potential side effects, and ensure safe and effective treatment. CoreAge Rx’s program includes ongoing medical support as part of its treatment structure, which contributed to its top ranking.

Health Connect Alliance’s review also provides broader clinical context about GLP-1 medications and their role in weight management. GLP-1 receptor agonists, including semaglutide and tirzepatide, mimic a naturally occurring hormone involved in regulating appetite and blood sugar. These medications slow gastric emptying, increase feelings of fullness, reduce appetite signals, and help stabilize blood sugar levels.

According to Health Connect Alliance, clinical research has shown that semaglutide may support reductions of approximately 10–15% of body weight, while tirzepatide may support reductions of approximately 15–26% when combined with lifestyle modifications and medical supervision. The platform notes that treatment outcomes vary based on individual health factors and adherence to treatment protocols.

Health Connect Alliance also explains that telehealth providers have expanded access to GLP-1 medications by enabling patients to complete medical consultations remotely and receive prescribed medications through direct-to-door delivery. The platform states that telehealth-based treatment programs can offer convenience, accessibility, and structured medical supervision.

As part of its rankings, Health Connect Alliance compared CoreAge Rx with other GLP-1 providers including Mochi Health, Ro, Noom, Remedy Meds, Hers, MEDVI, Eden, MyStart, and Clinic Secret. CoreAge Rx achieved the highest rating among all reviewed providers and was named the platform’s #1 overall recommendation.

Health Connect Alliance’s evaluation framework emphasizes that individuals seeking GLP-1 medications should verify provider medical credentials, confirm medication sourcing, review treatment policies, and ensure that licensed healthcare professionals are involved in prescribing and monitoring treatment.

The organization also highlights that legitimate GLP-1 providers require medical consultation prior to prescribing medication. This consultation allows licensed healthcare professionals to evaluate patient medical history, assess treatment eligibility, and ensure appropriate clinical oversight.

Health Connect Alliance describes its rankings and provider reviews as educational resources designed to help individuals make informed decisions about GLP-1 treatment programs. The platform states that its evaluation methodology focuses on medical supervision, treatment quality, safety standards, and transparency.

With its 9.9 out of 10 rating, Editor’s Choice designation, and #1 overall ranking among more than 48 reviewed providers, CoreAge Rx emerged as Health Connect Alliance’s highest-rated GLP-1 provider for weight management in 2026, reflecting the platform’s evaluation of medical supervision, personalized treatment plans, and access to FDA-approved semaglutide and tirzepatide.

For more info, visit: https://www.healthconnectalliance.com/glp-1/best

Media Contact

Organization: Health Connect Alliance

Contact Person: Ro Budo

Website: https://www.healthconnectalliance.com/

Email: Send Email

Contact Number: +13055550329

City: Miami

State: FL 33101

Country:United States

Release id:41550

The post Health Connect Alliance Names CoreAge Rx Best GLP-1 Provider for Weight Management in 2026, Awards 9.9-10 Rating and Editor’s Choice Designation appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section

file

Review Milestone: Why 300+ Patients Rated CoreAge Rx Among the Best in Online Weight Management Telehealth

Wichita Falls, TX 76302, United States, 18th Feb 2026 – CoreAge Rx, a telehealth platform focused on weight management and prescription treatment delivered through a fully online model, has reported a significant review milestone, with more than 300 patients providing positive feedback highlighting the platform’s onboarding experience, ongoing support, and overall care journey. According to CoreAge Rx, the growing number of patient reviews reflects a streamlined telehealth experience designed to provide accessible and professionally supervised weight management services.

The milestone underscores CoreAge Rx’s continued focus on delivering weight management care through a digital platform that allows patients to complete consultations remotely, receive physician evaluation, and access prescription treatment when appropriate. The company states that patient feedback consistently points to the clarity of the onboarding process and the structured approach to guiding patients through each stage of their care.

According to information provided by CoreAge Rx, patients begin the process by completing an online health assessment, which is reviewed by licensed medical professionals. This evaluation allows physicians to determine eligibility and develop individualized treatment plans based on each patient’s medical profile and weight management goals. The company reports that this structured onboarding system helps ensure that patients understand their care plan and receive appropriate medical supervision.

CoreAge Rx reports that ongoing support is another key factor contributing to patient satisfaction. Rather than limiting care to a one-time consultation, the platform provides continued access to medical guidance and treatment monitoring. Patient reviews provided to the company highlight the importance of continued communication and support throughout the weight management process, allowing patients to remain engaged and informed as they progress through treatment.

The company states that its telehealth platform is designed to remove many of the traditional barriers associated with in-person care. By enabling patients to complete evaluations and receive prescriptions remotely, CoreAge Rx provides a convenient alternative to traditional clinic visits. This remote care model allows patients to access weight management services from their home environment, reducing the need for travel and scheduling constraints.

CoreAge Rx also reports that physician supervision is a central component of its care model. According to the company, board-certified medical professionals review patient information, determine eligibility, and prescribe medications when appropriate. This physician-guided approach helps ensure that treatment decisions are based on individual health profiles and medical evaluation.

The company further states that prescription medications, when approved, are shipped directly to patients, allowing individuals to begin treatment without delays associated with traditional pharmacy visits. This delivery model supports the company’s goal of providing accessible and convenient weight management care through its telehealth platform.

According to CoreAge Rx, the review milestone reflects the company’s continued growth and patient engagement in the telehealth weight management space. The company reports that patient feedback consistently highlights the structured onboarding process, physician-guided care, and ongoing support as key factors contributing to the overall patient experience.

CoreAge Rx states that its digital-first approach is designed to provide patients with a clear and structured pathway, beginning with initial assessment, followed by physician evaluation, treatment approval when appropriate, and continued support. This step-by-step process is intended to ensure that patients receive care aligned with their individual needs.

The company reports that its telehealth model is built around accessibility, convenience, and physician oversight, allowing patients to access professional weight management care without requiring in-person clinic visits. According to CoreAge Rx, this approach reflects its commitment to providing modern healthcare solutions through digital technology.

CoreAge Rx further reports that the milestone of more than 300 patient reviews represents an important indicator of patient engagement and experience within its platform. The company states that patient feedback continues to inform its ongoing efforts to provide structured, physician-supervised weight management care through telehealth.

As telehealth adoption continues to expand, CoreAge Rx reports that its focus remains on maintaining a streamlined patient experience from onboarding through ongoing care. The company states that its review milestone reflects its continued commitment to delivering accessible, physician-guided weight management services through a fully online platform.

For more information, visit https://www.coreagerx.com/

Inquiries can be submitted through the official website contact page.
 

Media Contact

Organization: CoreAge Rx

Contact Person: Ella Jones

Website: https://www.coreagerx.com/

Email: Send Email

Contact Number: +19404004927

City: Wichita Falls

State: TX 76302

Country:United States

Release id:41548

Disclaimer: This content is provided for informational purposes only and does not constitute medical advice. Medical treatments require evaluation and prescription by licensed healthcare professionals.

The post Review Milestone: Why 300+ Patients Rated CoreAge Rx Among the Best in Online Weight Management Telehealth appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section

file

American Made GLP-1 Names CoreAge Rx As Best GLP-1 Provider for 2026

Miami, FL 33101, United States, 18th Feb 2026 – American Made GLP-1, a US- based healthcare resource dedicated to reviewing and comparing GLP-1 treatment providers, has released its latest rankings of telehealth platforms offering physician-supervised GLP-1 programs for weight management, naming CoreAge Rx as the #1 GLP-1 Provider and awarding the platform an outstanding 4.9 out of 5 rating. The independent review evaluated more than 10 U.S.-based telehealth providers and recognized CoreAge Rx with the designation “Editor’s Choice,” citing its medication quality, physician oversight, patient satisfaction, and comprehensive telehealth care model.

According to American Made GLP-1, the rankings were based on several key criteria, including the quality of GLP-1 medications prescribed, physician qualifications, treatment personalization, regulatory compliance, patient experience, and overall care quality. CoreAge Rx ranked at the top of the list due to its physician-supervised programs using FDA-approved GLP-1 medications such as semaglutide and tirzepatide, along with individualized treatment plans designed to support long-term weight management outcomes.

The rankings page published by American Made GLP-1 lists CoreAge Rx as its top recommendation, noting that the platform provides personalized telehealth-based treatment programs overseen by board-certified physicians with expertise in metabolic health and obesity medicine. The review highlights that CoreAge Rx offers a structured medical process that includes a comprehensive online health assessment, physician consultation, personalized treatment planning, and medication delivery directly to patients’ homes.

In its summary overview, American Made GLP-1 states that CoreAge Rx stands out among telehealth providers due to its commitment to personalized medical care, physician oversight, and ongoing patient monitoring. The platform’s telehealth model enables patients to begin treatment within approximately 24 to 48 hours following physician approval, allowing for timely access to medically supervised weight management care.

The editorial review identifies physician-guided treatment as a key factor in CoreAge Rx earning the #1 ranking. According to American Made GLP-1, CoreAge Rx connects patients with board-certified physicians who conduct comprehensive medical evaluations before prescribing treatment. These physicians develop individualized dosing protocols based on each patient’s medical profile and monitor patient progress throughout the treatment process to ensure safe and effective outcomes.

Medication quality and regulatory compliance were also highlighted as important ranking factors. CoreAge Rx prescribes GLP-1 medications that contain FDA-approved active ingredients, including semaglutide and tirzepatide, which are prepared by licensed compounding pharmacies that meet regulatory standards. American Made GLP-1 also notes that CoreAge Rx has earned LegitScript certification, confirming that the company meets strict requirements for telehealth safety, transparency, and pharmacy compliance.

American Made GLP-1 reports that CoreAge Rx’s weight management programs include ongoing physician supervision, progress monitoring, and personalized adjustments to treatment plans as needed. This continuous care model ensures that patients receive consistent medical oversight throughout their treatment journey, helping support sustainable and medically supervised weight management.

The review also emphasizes CoreAge Rx’s patient support infrastructure. According to American Made GLP-1, CoreAge Rx provides patients with access to dedicated care coordinators, nutritional guidance, and progress tracking tools. These services are designed to help patients remain engaged with their treatment plan and maintain consistency under physician supervision.

Shipping and accessibility were additional factors considered in the rankings. CoreAge Rx provides free standard shipping on prescribed medications, ensuring convenient access for patients nationwide. The telehealth platform serves eligible patients in most U.S. states, allowing individuals to receive physician-guided weight management care regardless of geographic location.

American Made GLP-1 also highlights reported patient outcomes associated with physician-supervised GLP-1 treatment programs. According to the review, patients participating in structured GLP-1 programs commonly experience measurable weight management progress over time. Reported data indicates that patients typically achieve a reduction of approximately 10 percent to 26 percent of body weight within 12 months under physician supervision, with many patients reporting improvements in energy levels and overall well-being.

The publication also notes that CoreAge Rx’s treatment programs are designed with flexibility in mind. Patients complete an initial consultation and comprehensive health evaluation, after which physicians determine eligibility and develop personalized treatment plans. CoreAge Rx offers semaglutide programs starting at $299 per month and tirzepatide programs starting at $399 per month, with physician supervision and ongoing support included as part of the program.

American Made GLP-1 describes itself as a trusted U.S.-based resource that provides information and independent comparisons of GLP-1 treatment providers. The organization states that its rankings are based on objective evaluation criteria, including medical quality, physician oversight, patient experience, and regulatory compliance, with the goal of helping patients make informed healthcare decisions.

With its 4.9 out of 5 rating and designation as the #1 GLP-1 Provider, CoreAge Rx emerged at the top of American Made GLP-1’s review of telehealth platforms offering physician-supervised GLP-1 programs. The recognition reflects the platform’s focus on medical oversight, treatment personalization, regulatory compliance, and patient-centered telehealth care for weight management.

For more info, visit: https://www.americanmadeglp1.com/reviews/coreage-rx

 

Media Contact

Organization: American Made GLP-1

Contact Person: Paul Hard

Website: https://www.americanmadeglp1.com/

Email: Send Email

Contact Number: +13035550187

City: Denver

State: CO 80202

Country:United States

Release id:41549

Disclaimer: This content is provided for informational purposes only and does not constitute medical advice. Medical treatments require evaluation and prescription by licensed healthcare professionals.

The post American Made GLP-1 Names CoreAge Rx As Best GLP-1 Provider for 2026 appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section

file

GLP-1 Planet Names CoreAge Rx Top Provider Out of 78 Compared, Awarding 9.6-10 Rating and Recognizing $99/Month Flat Pricing for Weight Management Care

Portland, OR 97201, United States, 18th Feb 2026 – An independent GLP-1 comparison platform, GLP1Planet.com, has awarded CoreAge Rx a rating of 9.6 out of 10 and identified it as its recommended provider after reviewing 78 GLP-1 medication services. According to GLP-1 Planet’s published review, the evaluation focused on key criteria including pricing transparency, service quality, medication access, and patient support. Based on these findings, CoreAge Rx was recognized as offering one of the most competitive and transparent pricing models in the GLP-1 market, with a flat monthly price of $99.

GLP-1 Planet reported that CoreAge Rx’s pricing model includes virtual doctor consultation, GLP-1 medication, ongoing medical support and monitoring, and delivery directly to the patient’s door. The platform noted that the $99 monthly price remains consistent regardless of dose, and it does not include hidden fees or surprise charges. This pricing structure, combined with service quality and access to licensed healthcare providers, contributed to CoreAge Rx receiving the platform’s highest overall rating among the providers reviewed.

According to GLP-1 Planet’s analysis, CoreAge Rx offers access to GLP-1 medications including semaglutide and tirzepatide through its telemedicine platform. The review stated that CoreAge Rx provides consultations with licensed healthcare providers who evaluate patients through an online medical assessment process before determining whether GLP-1 medication is appropriate. If prescribed, the medication is shipped directly to the patient with ongoing medical support.

GLP-1 Planet also reported that CoreAge Rx operates with HIPAA compliance and employs licensed physicians to oversee care. The platform highlighted that CoreAge Rx provides multiple support channels, including phone support at 1-888-COREAGE, email support at support@coreagerx.com, and live chat availability during weekday hours from 8 AM to 8 PM Eastern Time.

The independent review noted that CoreAge Rx offers a comprehensive telemedicine program that includes an initial medical questionnaire, physician evaluation, and medication delivery with continued monitoring. GLP-1 Planet reported that CoreAge Rx provides follow-up care, dedicated coaching support, and bi-weekly monitoring as part of its service model. Additional features identified in the review include free shipping, mobile app access, and a cancellation policy that allows patients to cancel at any time, as well as a 30-day money-back guarantee.

GLP-1 Planet’s review also stated that semaglutide and tirzepatide, available through CoreAge Rx, are GLP-1 medications used in weight management programs. According to the platform, semaglutide is a GLP-1 receptor agonist that works by reducing appetite, slowing digestion, and helping individuals feel full longer. Tirzepatide is a dual GIP/GLP-1 receptor agonist that provides a dual-action approach to weight management.

The platform reported that CoreAge Rx received its 9.6 out of 10 rating based on evaluation categories including pricing transparency, medication options, service quality, and customer support. GLP-1 Planet’s published review described CoreAge Rx as one of the top-rated GLP-1 medication providers, citing its combination of flat pricing, licensed healthcare provider oversight, and telemedicine-based care delivery.

About GLP-1 Planet

GLP-1 Planet describes itself as a platform that compares GLP-1 medication providers and publishes independent reviews based on factors including pricing, service transparency, medication availability, and support quality. The platform evaluates providers to help individuals understand available options and compare services offering GLP-1 medications for weight management.

GLP-1 Planet’s comparison of 78 GLP-1 providers included analysis of pricing models, service features, medication availability, and customer support channels. Based on its evaluation, the platform identified CoreAge Rx as its recommended provider due to its transparent pricing model, access to licensed healthcare providers, and comprehensive telemedicine support.

Review Methodology

According to GLP-1 Planet’s published review, its evaluation process involved comparing multiple GLP-1 medication providers across key criteria including pricing transparency, medication options, customer support, and care quality. The platform’s analysis identified CoreAge Rx as offering the most transparent pricing model among the providers reviewed, with a flat monthly price of $99 that includes consultation, medication, and ongoing support.

The review also evaluated service features such as telemedicine consultations, medication delivery timelines, support availability, and follow-up care. CoreAge Rx’s combination of telemedicine access, licensed healthcare provider oversight, and ongoing monitoring contributed to its overall rating of 9.6 out of 10.

Full details of the CoreAge Rx review are available at https://www.glp1planet.com/coreage-rx-reviews.

About CoreAge Rx

CoreAge Rx is a telemedicine provider offering GLP-1 medications including semaglutide and tirzepatide for weight management. The company provides a telemedicine process that begins with a comprehensive medical assessment, followed by evaluation by a licensed healthcare provider. If prescribed, medication is shipped directly to the patient, along with ongoing medical support and monitoring.

CoreAge Rx provides virtual consultations, medication delivery, follow-up care, and access to licensed healthcare providers through its telemedicine platform. The company operates with HIPAA compliance and offers multiple support channels, including phone, email, and live chat.

For more info, visit: https://www.glp1planet.com/coreage-rx-reviews

Media Contact

Organization: GLP-1 Planet

Contact Person: Amber Toay

Website: https://www.glp1planet.com/

Email: Send Email

Contact Number: +15035550261

City: Portland

State: OR 97201

Country:United States

Release id:41551

Disclaimer: This content is provided for informational purposes only and does not constitute medical advice. Medical treatments require evaluation and prescription by licensed healthcare professionals.

The post GLP-1 Planet Names CoreAge Rx Top Provider Out of 78 Compared, Awarding 9.6-10 Rating and Recognizing $99/Month Flat Pricing for Weight Management Care appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section

file

Health Connect Alliance Features CoreAge Rx as Top Pick in Comprehensive GLP-1 Buyer’s Guide

Miami, FL 33101, United States, 18th Feb 2026 – Health Connect Alliance, a health education platform focused on empowering consumers with unbiased medication guidance, has named CoreAge Rx as its #1 recommended provider in its GLP-1 buyer’s guide. According to HealthConnectAlliance.com, CoreAge Rx was selected as the #1 recommended provider across semaglutide, tirzepatide, and overall GLP-1 categories for weight management. The rankings appear in Health Connect Alliance’s published guide, “Best Place to Get GLP-1 Medications,” which provides information about providers offering access to GLP-1 receptor agonists including semaglutide and tirzepatide.

The guide was written by Sarah Chen, MS in Biomedical Sciences, and medically reviewed by Emily Patel, MS in Pharmaceutical Sciences. Health Connect Alliance states that its guide is intended to help individuals identify providers offering GLP-1 medications with medical supervision, transparent pricing, and treatment support. The platform also states that its content is designed to help individuals make informed decisions regarding GLP-1 medications and treatment options.

Health Connect Alliance lists CoreAge Rx in the #1 position and designates the provider as “Editor’s Choice.” The guide assigns CoreAge Rx a rating of 9.9 out of 10 and an A+ grade. CoreAge Rx appears at the top of the rankings in comparison with other providers included in the guide.

According to Health Connect Alliance, CoreAge Rx offers a premium GLP-1 program that includes FDA-approved semaglutide and tirzepatide. The guide states that CoreAge Rx provides personalized treatment plans and access to board-certified physicians. Health Connect Alliance also states that CoreAge Rx provides ongoing medical support as part of its GLP-1 program.

The rankings published by Health Connect Alliance include additional providers offering GLP-1 medications. These providers include Mochi Health, Ro, Noom, Remedy Meds, Hers, MEDVI, Eden, MyStart, and Clinic Secret. Health Connect Alliance presents these providers as part of its comparison of GLP-1 medication programs.

Health Connect Alliance states that GLP-1 receptor agonists including semaglutide and tirzepatide are medications used in weight management programs. The guide explains that these medications require valid prescriptions and consultation with licensed healthcare professionals before prescribing. Health Connect Alliance states that licensed healthcare professionals may include licensed physicians, nurse practitioners, or physician assistants.

The guide states that GLP-1 medication providers should conduct comprehensive health assessments and medical history reviews before prescribing treatment. Health Connect Alliance also states that providers may conduct follow-up appointments to monitor patient progress and side effects.

Health Connect Alliance states that GLP-1 medication providers may offer medications that are FDA-approved or sourced from licensed compounding pharmacies. The guide states that providers should be transparent about medication source, manufacturing, and quality standards. Health Connect Alliance also states that proper storage, shipping, and quality assurance protocols are important considerations.

Health Connect Alliance states that telehealth providers may offer online consultation processes and prescription access. The guide explains that telehealth providers may offer consultation processes conducted through video or online questionnaires. Health Connect Alliance also states that telehealth providers may offer prescription access and medication delivery.

The guide states that telehealth providers may offer ongoing medical supervision and access to medical staff. Health Connect Alliance also states that providers may offer structured treatment plans and continued medical oversight.

Health Connect Alliance states that choosing a GLP-1 medication provider involves verifying medical credentials, comparing pricing and services, and reviewing treatment structure. The guide also states that individuals should review provider policies and confirm medication sources.

Health Connect Alliance states that medications should not be purchased without valid prescriptions from licensed healthcare providers. The guide also states that individuals should consult qualified healthcare professionals before starting any GLP-1 medication or weight management program.

Health Connect Alliance states that its rankings are based on its evaluation of GLP-1 medication providers offering medical supervision and treatment programs. The platform provides provider comparisons, educational resources, and informational guides related to GLP-1 medications.

Health Connect Alliance describes itself as a health education platform that provides informational content related to GLP-1 medications and treatment options. The platform states that its content is intended for informational purposes only and is not intended as medical advice.

With a rating of 9.9 out of 10 and designation as the #1 recommended provider, CoreAge Rx is listed by Health Connect Alliance as the top-ranked provider in its GLP-1 buyer’s guide covering semaglutide, tirzepatide, and GLP-1 treatment options for weight management. Health Connect Alliance presents CoreAge Rx as the top-ranked provider among the GLP-1 medication providers included in its published rankings.

Health Connect Alliance states that its guide is intended to help individuals evaluate GLP-1 medication providers and understand available treatment options. The platform continues to publish guides, reviews, and informational resources related to GLP-1 medications and treatment programs.

For more info, visit: https://www.healthconnectalliance.com/glp-1/best

Media Contact

Organization: Health Connect Alliance

Contact Person: Ro Budo

Website: https://www.healthconnectalliance.com/

Email: Send Email

Contact Number: +13055550329

City: Miami

State: FL 33101

Country:United States

Release id:41552

Disclaimer: This content is provided for informational purposes only and does not constitute medical advice. Medical treatments require evaluation and prescription by licensed healthcare professionals.

The post Health Connect Alliance Features CoreAge Rx as Top Pick in Comprehensive GLP-1 Buyer’s Guide appeared first on King Newswire. This content is provided by a third-party source.. King Newswire makes no warranties or representations in connection with it. King Newswire is a press release distribution agency and does not endorse or verify the claims made in this release. If you have any complaints or copyright concerns related to this article, please contact the company listed in the ‘Media Contact’ section

file